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Abstract
Background: Interleukin (IL)-33 is a dual cytokine with both an alarmin role and a T helper 2 cell (Th2)-like inducing
effect. It is involved in the pathogenesis of rheumatoid arthritis (RA) and its models; we recently demonstrated that
exogenous IL-33 could inhibit collagen-induced arthritis (CIA) in C57BL/6 mice. However, its pathophysiological role
in RA is unclear. Indeed, mice deficient in the IL-33 receptor ST2 show reduced susceptibility to arthritis, and the
disease is not modified in IL-33-deficient mice. We examined the immune response in wild-type (WT) and IL-33-deficient
mice with CIA. To further understand the role of endogenous IL-33 in inflammatory diseases, we studied its role in a skin
psoriasis model. Mice on a C57BL/6 background were deficient in IL-33 but expressed lacZ under the IL-33 promoter.
Therefore, IL-33 promotor activity could be analyzed by lacZ detection and IL-33 gene expression was analyzed by X-Gal
staining in various mice compartments. Frequencies of CD4+FoxP3+ regulatory T cells (Tregs) and Th1 and Th17 cells
were evaluated by flow cytometry in WT and IL-33-/- mice. Bone resorption was studied by evaluating osteoclast activity
on a synthetic mineral matrix. Psoriasis-like dermatitis was induced by application of imiquimod to the skin of mice.
Results: Severity of CIA was similar in IL-33-/- and WT littermates. Joints of IL-33-/- mice with CIA showed IL-33 promotor
activity. In mice with CIA, frequencies of Tregs, Th1 and Th17 in the spleen or lymph nodes did not differ between the
genotypes; osteoclast activity was higher but not significantly in IL-33-/- than WT mice. Psoriasis development did not
differ between the genotypes.
Conclusions: Despite its expression in the synovium of arthritic mice and normal keratinocytes, IL-33 is not required for
CIA development in arthritis or psoriasis. Its absence does not induce a T cell shift toward Th1, Th17 or Treg
subpopulations. Altogether, these data and our previous ones, showing that exogenous IL-33 can almost completely
inhibit CIA development, suggest that this cytokine is not crucial for development of chronic inflammation. Studies of RA
patients are needed to determine whether treatment targeting the IL-33/ST2 axis would be effective.
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Background
Interleukin (IL)-33 is a member of the IL-1 family, which
also includes IL-1α, IL-1β, IL-18, IL-36, IL-37, IL-38,
and the receptor antagonists IL-1Ra and IL-36Ra [1]. It
is localized in the cell nucleus [2] and was first described
as a cytokine passively released by necrotic epithelial
and endothelial cells with tissue damage during infection
or inflammatory diseases, thereby acting as an alarmin.
However, IL-33-expressing cells also include other cells
of stromal and parenchymal origin, such as macro-
phages, dendritic cells, mast cells, smooth muscle cells,
fibroblasts, glial cells, osteoblasts, synoviocytes, and
adipocytes.
IL-33 signals via a heteromeric receptor consisting of
ST2 and IL-1R accessory protein (IL-1RAcP). Several ac-
tivated immune cells and numerous nonimmune cells
respond to IL-33 via its receptor. Immune cells express-
ing IL-33 receptor include T helper 2 (Th2) cells (but
not Th1 and Th17), all polymorphonuclear neutrophils,
induced natural killer T cells, natural killer cells, B lym-
phocytes, macrophages, dendritic cells, and type 2 innate
lymphoid cells (ILC2) [3]. The expression pattern of IL-
33 receptor indicates that it is in the center of a complex
cellular network of immune and nonimmune cells [4].
IL-33 is considered to be a dual-role cytokine that can
both promote and reduce inflammation depending on
the tissue and cytokine environment. Its positive or
negative control of inflammation involves a complex
process. Its pro-inflammatory role is related to the in-
volvement of the IL-33/ST2 system in regulating each
phase of a generic inflammatory pathway. Indeed, when
tissues receive insults leading to inflammation, the major
sources of IL-33 are epithelial cells, endothelial cells, or
tissue macrophages. IL-33 then induces the production
of additional inflammatory mediators and amplifies the
inflammatory response. The anti-inflammatory role of
IL-33 is related to its capacity to suppress inflammation
by driving type 2 immunity. IL-33 acts by promoting M2
macrophage [5] or Th2 T cell differentiation. IL-33 can
also expand and induce high levels of IL-5 and IL-13
production by ILC2.
Some works suggest a functional role of the IL-33/ST2
axis in the pathogenesis of human and mouse arthritis.
In rheumatoid arthritis (RA) patients, IL-33 levels are
elevated in serum and synovial fluid [6, 7] and strong IL-
33 expression can be detected in endothelial cells and fi-
broblasts in the human RA synovium [8]. IL-33 induces
in vitro tumor necrosis factor (TNF) alpha and IL-8 pro-
duction by human mast cells within the synovium [9]. In
mouse models of experimental arthritis induced by ac-
tive immunization, such as collagen- and antigen-
induced arthritis, the use of ST2-knockout (KO) mice,
ST2 blockade, or injection of soluble ST2 led to de-
creased immune responses and severity of arthritis,
which suggested a pathogenic role for IL-33 signaling
through ST2 in these experimental models [10, 11].
However, K/BxN serum transfer-induced arthritis is re-
duced in ST2-knockout mice but does not differ in IL-
33-knockout and wild-type (WT) mice [12]. As well,
sST2, the soluble receptor for IL-33, has no effect on
collagen-induced arthritis (CIA) [13]. IL-33 deficiency
did not modify antigen-induced arthritis or CIA in
DBA/1 mice [14].
As RA, psoriasis is a chronic inflammatory disease,
and IL-33 may have a role in its pathogenesis. Indeed,
IL-33 level is increased in skin lesions of patients with
psoriasis [15] and is decreased after anti-TNF-α treat-
ment [16]. Its role as an alarmin is suggested by the
positive Köbner reaction, described as new psoriasis le-
sions after slight skin injury. The imiquimod (IMQ)-in-
duced psoriasiform dermatitis acts via Toll-like receptor
7 (TLR7) stimulation with daily application of Aldara®
cream, which contains IMQ [17].
These studies in arthritis models underscore the complex
nature of IL-33 and that it may also play a role in psoriasis.
Therefore, we used in vitro models to investigate whether
endogenous IL-33 administration can contribute to the
regulatory and inflammatory pathways culminating in the
pathology of chronic inflammatory diseases.
Methods
Mice
IL-33-/- mice were a gift from JP Girard and generated
as described [18]. In these mice, a β-geo insertion dis-
rupts production of the IL-33 protein, which is useful to
visualize the activity of the endogenous IL-33 promoter
via X-Gal staining (β-galactosidase activity). Heterozy-
gous IL-33+/- mice were generated by breeding C57BL/6
mice (Janvier Labs, Le Genest-Saint-Isle, France) to IL-
33-/- mice. Then IL-33+/- mice were bred together and
the resulting homozygous IL-33+/+ WT littermates were
used as controls in all experiments.
Collagen-induced arthritis (CIA) induction and evaluation
Arthritis was induced with native chicken collagen type
II (CII, MD Biosciences, Zürich, Switzerland). At 10 to
12 weeks of age, male C57BL/6 mice were injected intra-
dermally at the base of the tail with 50 μg CII emulsified
in complete Freund’s adjuvant (CFA, MD Biosciences).
On day 21, mice received a booster subcutaneous injec-
tion of CII emulsified in CFA. A blinded procedure was
used to monitor clinical and histological arthritis in all
four limbs, as previously described [19, 20].
Induction and evaluation of IMQ-induced psoriasis-like
dermatitis
Psoriasis was induced in mice with commercially avail-
able IMQ cream (5 %; Aldara cream; MEDA AB, Solna,
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Sweden). Male mice, 9 to 11 weeks old, received a daily
topical application of 62.5 mg IMQ cream on the shaved
back skin for 10 consecutive days. A blinded procedure
was used to monitor psoriasis-like skin inflammation.
Clinical scoring of psoriasis based on the human clinical
Psoriasis Area and Severity Index (PASI) was performed
daily. Three variables were evaluated – erythema, scal-
ing, and thickening – scored independently on a scale
from 0 to 4: 0, none; 1, slight; 2, moderate; 3, marked; 4,
very marked. The cumulative score was a total of the
three parameter scores ranging from 0 to 12. For histo-
logical assessment, skin samples from the back were
fixed in 10 % formalin for at least 24 h at room
temperature and embedded in paraffin. Deparaffinized
sections of 4 μm were stained with hematoxylin erythro-
sine saffron before microscopy observation (optical mi-
croscopy). Epidermal thickness was evaluated by using
Archimed software (Microvision Instruments, Les Ulis,
France). We averaged five to ten values for independent
fields of epidermis (from corneal layer to the basement
membrane zone) for each mouse.
β-galactosidase detection
Hind paws were dissected and fixed in a solution of glu-
taraldehyde 25 % for 2 to 4 h at room temperature. Knee
joints were injected with the chromogenic substrate X-
Gal (from the lacZ tissue staining kit, InvivoGene,
Toulouse, France) and incubated in the solution for 3 h
at 37 °C under shaking. The paws were washed overnight
in phosphate-buffered saline (PBS) 1X (37 °C). Sections of
7 μm were prepared and stained with hematoxylin and
eosin (H&E) before microscopy observation.
Skin samples were dissected and stored at -80° until
use. Skin cryosections of 5 μm were embedded in OCT,
then fixed for 10 min in PBS with 0.2 % glutaraldhehyde
and rinsed three times in washing buffer (MgCl2 2 mM,
Na desoxycholate 0.01 %, Igepal 0.02 %, PBS) for 5 min.
For ß-gal staining, slices were incubated overnight with
X-gal (1 mg/ml) in staining buffer (potassium ferricyan-
ide 6 mM, potassium ferrocyanide 6 mM), at 37 °C. Sec-
tions were then rinsed in PBS, distilled water and
counterstained with eosin. Blue color was detected by
light microscopy.
IL-33 detection by immunofluorescence
Paraffin sections (5 μm) were deparaffinized in a Zylene
mix of isomer solution (Carlo Erba Reagents, Val-de-
Reuil, France) and rehydrated in a graded alcohol series.
Then the sections were washed in distilled water and
boiled in a microwave oven for epitope retrieval in
sodium citrate buffer (10 mM, pH 6). Slides were incu-
bated with polyclonal goat immunoglobulin (Ig)G anti-
mouse IL-33 (Clone: Q8BVZ5, 1:200, R&D Systems,
Minneapolis, MN, USA) or control isotype (polyclonal
goat IgG, 1:200 R&D Systems), then washed in PBS
(5 min, three times) and incubated with donkey IgG
anti-goat IgG conjugated with Northern Lights 557
(1:200 R&D Systems) in darkness. Slides were counter-
stained with DAPI.
Osteoclastogenesis and bone resorption
For osteoclastogenesis assay, the anterior paws were dis-
sected to collect bone marrow cells. Then, for each
mouse, 2.105 cells were plated in triplicate on 96-well
plates with receptor activator of nuclear factor kappa B
ligand (RANKL) (100 ng/mL) and macrophage colony-
stimulating factor (M-CSF) (30 ng/mL) in 5 % CO2 at
37 °C. Cells were stained with TRAP (Acid Phosphatase,
Leukocyte TRAP Kit, Sigma-Aldrich, St Louis, MO,
USA) on day 5, and osteoclasts with ≥3 nuclei were
identified as TRAP-positive.
For bone resorption assay, bone marrow cells were iso-
lated as described above. Then, 4.105 cells were cultured
with mouse M-CSF (30 ng/ml) and mouse RANKL
(100 ng/ml) on an Osteo Assay plate (Corning Inc.,
Corning, NY, USA) containing a synthetic mineral
matrix with 5 % CO2 at 37 °C. At day 8, bone resorption
was analyzed. The experiment was performed in tripli-
cate wells for each mouse and one image was obtained
from one whole well. Number of resorption spots and
percentage resorption area were evaluated by using Ima-
geJ, and mean number from each triplicate experiment
was calculated.
Cell preparation and analysis
Leukocytes from the spleen were prepared by using a
cell strainer, and red blood cells were lysed in hemolytic
buffer (NH4Cl, KHCO3, and EDTA). Afferent and poplit-
eal lymph nodes were dissected out of the hind limbs
and leukocytes were prepared using a homogenizer.
Blood was collected by heart puncture, and for cell ana-
lysis, red blood cells were lysed in hemolytic buffer.
Leukocytes were stained with PercPCyc5.5-anti CD4
antibody (clone RM4-5) (BD Biosciences). The APC-
anti-Foxp3 Staining Set (clone FJK-16 s) (eBioscience,
San Diego, CA, USA) was used for intracellular staining.
To analyze Th1 and Th17 cells, 106 leukocytes were
stimulated with PMA (50 ng/ml) and ionomycin (1 μg/ml)
(Sigma-Aldrich) with monensin (BD Biosciences) for 4 h.
For intracellular interferon (IFN)-γ and IL-17 staining,
CD4+ cells were first stained with a surface marker and
permeabilized with Cytofix/Cytoperm (BD Biosciences),
then stained with the antibodies APC-anti-IFN-γ (clone
XMG1.2) or PE-anti-IL-17 (clone TC11-18H10) (BD Bio-
sciences). Flow cytometry involved use of FACS Calibur
(Becton Dickinson, Mountain View, CA, USA). Dead cells
were excluded by forward and side scatter characteristics
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(BD Biosciences) and results were analyzed by using Cell-
Quest Pro (BD Biosciences).
Results
Endogenous IL-33 is expressed in mouse joints
X-Gal staining of knee joints from IL-33-/- or WT IL-
33+/+ mice was used to evaluate IL-33 promotor activ-
ity in mice with or without arthritis. As expected, no
β-galactosidase activity was observed in joints from
WT mice, without the IL-33–LacZ construction
(Fig. 1a and b). In contrast, LacZ expression was
detected in IL-33-/- mice without CIA, so the IL-33
promoter was constitutively active in naive mice
(Fig. 1c and d). We then analyzed the expression of
IL-33 in mice with CIA at day 10 or 35 and found
LacZ expression in joint tissues (Fig. 1e–h).
Collagen-induced arthritis is not affected by lack of IL-33
We then investigated the effect of IL-33 deficiency on
the development of CIA. Clinical scoring revealed that
the course of arthritis was similar in IL-33-/- and WT
mice (Fig. 2a). Moreover, the mean maximal arthritis
Fig. 1 LacZ expression in mouse joints with or without collagen-induced arthritis (CIA). Knee joint sections of mice without CIA (a, b, c, d) or with
CIA (day 10 (e, f) or day 35 (g, h) after CIA induction were stained with X-gal, and blue staining was observed at × 10 (a, c, e, g) or × 20 (h) or × 40
(b, d, f) magnification. IL-33+/+ wild-type (WT) mice (a, b) and interleukin (IL)-33-/- mice (c, d, e, f, g, h) were analyzed. Slides are representative of
eight WT mice, eight IL-33-/- mice without CIA, five IL-33-/- mice at day 10 after CIA, and four IL-33-/- mice at day 35 after CIA
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Fig. 2 IL-33 deficiency does not affect collagen-induced arthritis. IL-33-/- mice (n = 13) open circles and WT mice (n = 12, closed circles) were
injected intradermally with chicken collagen II emulsified in complete Freund’s adjuvant (CFA) on days 0 and 21. a Clinical arthritis scores. b Mean
maximal arthritis score (Amax). c Mean onset of arthritis. Data are mean ± SEM and are representative of one experiment in two similar experiments
IL interleukin, WT wild-type
Fig. 3 Effect of IL-33 deficiency on T helper (Th) cell subsets. Mice as in Fig. 2 were killed 45 days after the first injection. Splenocytes from nine
mice randomly selected in both groups were stained with fluorochrome-conjugated anti-CD4, anti-FoxP3, anti-IFN-γ and anti-IL-17 antibodies.
Regulatory T cells (Tregs) were defined as CD4+ FoxP3+ cells, and Th1 and Th17 cells were defined as CD4+ IFN-γ+ and CD4+ IL-17+ cells, respectively. The
proportion of FoxP3+ (a), IFN-γ+ (b), and IL-17+ cells (c) among CD4+ cells are shown. Data are representative of one experiment in two similar experiments.
IFN interferon, IL interleukin, WT wild-type
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score (Amax) and onset of arthritis did not differ in IL-
33-/- and WT mice (Fig. 2b and c). Finally, histological
examination at day 45 revealed no difference between
IL-33-/- and WT mice in joint inflammation score
(0.71 ± 0.23 vs. 0.74 ± 0.18) and destruction score
(0.38 ± 0.16 vs. 0.38 ± 0.13).
Effect of endogenous IL-33 on T-cell subset frequencies
during CIA
Because IL-33 was found to induce a type 2 immune re-
sponse [21–23] and regulatory T cell (Treg) expansion
[24], we wondered whether, despite a lack of IL-33 defi-
ciency effect on CIA, the lack of this cytokine could lead
to a modified T cell profile in CIA. Therefore, we evalu-
ated the frequencies of CD4+ T cell subpopulations at
45 days after CIA induction in WT and IL-33-/- mice.
Frequencies of regulatory T cells defined as CD4+FoxP3+
cells and Th1 or Th17 cells in the spleen (and lymph
nodes, data not shown) did not differ between IL-33-/-
and WT mice during CIA (Fig. 3).
In vitro activity and differentiation of osteoclasts from
arthritic IL-33-/- mice
IL-33 protects against bone resorption, but its role in os-
teoclastogenesis is unclear [25]. To examine whether IL-
33 deficiency affects osteoclast formation during CIA,
osteoclasts were generated from mouse bone marrow.
The number of osteoclasts was similar for both IL-33-/-
and WT mice, so the absence of IL-33 did not affect in
vitro differentiation of osteoclast precursors in the bone
marrow of mice at day 45 of CIA (Fig. 4a). We then ex-
amined in vitro bone resorption activity of mouse osteo-
clasts and showed that number of resorption spots and
percentage resorption area were lower, but not signifi-
cantly, in WT than IL-33-/- mice (Fig. 4b), especially
when excluding mice without any arthritis from the ana-
lysis (Fig. 4c). Therefore, IL-33 might be involved in
bone resorption during CIA.
Psoriasis-like skin inflammation development is not
impaired in IL-33-/- mice
IL-33 is suggested to play a role in human skin psoriasis.
This disease could also affect joints in psoriatic arthritis.
Thus, we aimed to compare IMQ-induced psoriasis-like
skin inflammation in WT and IL-33-/- mice. At 2 days
after the start of IMQ application for 10 days, the back
skin of mice started to display signs of skin erythema
and further thickness and scales from day 3. Typical ex-
amples of the psoriatic-like skin lesions are shown in
Fig. 5 (c-f ). Histological slides of the skin 11 days after
the first application of IMQ are shown in Fig. 5 (g-i). In-
dependent scores in a representative experiment are in
Fig. 4 Osteoclastogenesis and bone resorption activity in WT and IL-33-/- mice with collagen-induced arthritis (CIA). Mice as in Fig. 2 were evaluated
for osteoclastogenesis (a) and bone resorption activity (b) in WT (n = 8, black bars) and IL-33-/- (n = 8, open bars) mice at day 45 after CIA induction.
Bone resorption was evaluated by number of spots with resorption and percentage resorption area. Arthritic mice (c) were defined as mice
with a clinical score of arthritis >0 for at least 1 day during the CIA course (IL-33-/-, n = 6; WT n = 5). Data are mean ± SEM. IL interleukin, WT wild-type
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Fig. 6 (a-c). From day 3 onward, the total inflammation
score for severity continually increased, up to the end of
the experiment. The total scores (thickness, scales and
erythema) were similar in IL-33-/- and WT mice (Fig. 6d).
The two genotypes did not differ. Mean epidermal thick-
ness was quantified on skin histological slides and was
comparable between IL-33-/- and WT mice (40.9 and
44.2 μm, p = 0.39, Student’s t test, Fig. 6e), in accordance
with the clinical analysis.
We found that the IL-33 promotor was active within
the joints of mice during CIA, so we wondered whether
IL-33 was expressed in the skin during IMQ-induced
skin inflammation in mice. We first directly observed
IL-33 expression by immunofluorescence staining of IL-
33 in skin samples 11 days after daily application of
IMQ. As expected, IL-33-/- mice showed no expression
of IL-33 (Fig. 7a), whereas WT mice with or without
IMQ application showed nuclear expression of IL-33 in
keratinocytes (Fig. 7b-c). We also evaluated IL-33 pro-
moter activity by X-Gal staining in the skin of IL-33-/-
mice (Fig. 7d-e), which showed a similar pattern as in
WT mice with IL-33 staining, namely lacZ staining
within the basal layers of the epidermis (Figure D). As
expected, no lacZ staining was detected in WT mice
(Figure E).
Discussion
In this study, we investigated the impact of IL-33 defi-
ciency in two models of chronic inflammation, namely
CIA in C57BL/6 mice and IMQ-induced psoriasis in
mice. Arthritis and psoriasis developed independent of
IL-33 expression, despite IL-33 promotor activation
within the synovium during the course of arthritis and
IL-33 expression in skin. Interestingly, IL-33 was de-
tected in the synovium of RA patients [6] and in lesions
of patients with psoriasis. Serum IL-33 levels are also
Fig. 5 Clinical and histological evaluation of imiquimod (IMQ)-induced skin inflammation in mice. C57BL/6 mice, interleukin (IL)-33-/- and wild-type (WT),
were daily treated with IMQ cream or vehicle cream (Vaseline), applied on the shaved back skin. Phenotypical presentation of mouse back
skin after shaving and before cream application showed a thin and white skin without scales (a). These characteristics were maintained
4 days after Vaseline application (b). In contrast, IMQ-treated mice showed erythema, infiltration, and scales, which appeared at day 4 in
both IL-33-/- (c) and WT (d) mice. Skin inflammation was increased similarly in both groups, with more scales and increased infiltration at
day 9 in both IL-33-/- (e) and WT (f) mice. Histological slides (×200) of back skin 11 days after IMQ application in IL-33-/- mice (g) and WT
mice (h) showed acanthosis and hyperkeratosis. Control WT mice without IMQ application is shown in (i)
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increased in RA [5, 7] and psoriasis [26]. However, de-
creased epidermal IL-33 level could be rapid but transi-
ent, as demonstrated in experimentally induced psoriatic
lesions in humans, and increased after 7 days [27]. Mice
and humans showed strong differences in epidermal ex-
pression and regulation of IL-33, which could explain
the inability of this model to reveal the pathophysio-
logical role of IL-33 in psoriasis [28]. We cannot exclude
that a compensation pathway of inflammation could be
responsible for a lack of difference between WT and IL-
33-/- mice. A recent study showed that TLR7 depend-
ence of IMQ-induced psoriatic lesions could be
abolished only in MyD88-deficient mice and the inhibition
of IL-1-alpha/beta or IL-1R1 was not sufficient [29].
The lack of IL-33 involvement in our model of CIA
confirms findings from studies of other models of RA,
namely antigen-induced arthritis and CIA [14] and K/
BN serum transfer-induced arthritis [12]. In agreement
with these observations, IL-33-deficient mice showed no
difference from WT mice in experimental autoimmune
encephalomyelitis, a model of multiple sclerosis, Con A-
induced hepatitis, or streptozocyn-induced diabetes [30].
Conversely, IL-33 deficiency ameliorated dextran so-
dium sulfate-induced colitis and conferred resistance to
lipopolysaccharide-induced endotoxinic shock in mice
[29]. These two models involve innate immunity,
whereas acquired immunity is involved in the above
models of inflammation. IL-33 may be a major amplifier
of systemic innate rather than acquired immunity.
Some studies of the K/BxN serum transfer model
found reduced severity of arthritis in ST2-deficient mice
[11]. These data suggest a crucial role of this receptor in
the development of joint inflammation. This finding
contrasts with all concordant studies of experimental
chronic autoimmunity with IL-33-deficient mice. A simi-
lar contrast has been observed in other models such as
Fig. 6 Imiquimod (IMQ)-induced skin inflammation develops independent of IL-33. IL-33-/- (n = 6) or WT (n = 6) mice were treated daily with IMQ
cream. Erythema, scales, and thickness of the back skin were scored daily on a scale from 0 to 4 (a-c). The cumulative score (erythema plus scales
plus thickness) is depicted (d). Data are mean score ± SEM of six mice per group. Epidermal thickness was measured on histological slides of the
skin at day 11 (e), and scores are individual scores for all mice (n = 6 in both groups). The results are representative of two experiments (n = 19). IL
interleukin, WT wild-type
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OVA-induced airway inflammation [30]. One hypothesis
to explain these apparent discrepancies is the existence
of another ligand of ST2, even if to date, no study has
revealed a potential candidate.
RA and psoriasis are chronic inflammatory diseases
characterized by increased frequency of Th1 and Th17
cells. An increase in Th17 frequency and a decrease in
Tregs frequency were observed in blood of patients with
active RA [31]. Similarly, an increase in IL-17 level was
observed in the skin of patients with psoriasis. Moreover,
these patients showed a positive correlation between
Th17/Treg cell ratio in the skin and disease activity, to-
gether with a decrease in the frequency and suppressive
activity of Tregs [32], and anti-IL-17 antibody treatment
conferred excellent therapeutic responses in patients
with psoriasis [33].
We found no difference between IL-33-/- and WT
mice in frequencies of Treg, Th1, and Th17 cells in the
spleen and lymph nodes with either CIA or psoriasis.
Given the role of the cells in both models, this finding
may explain why disease severity is not modified in the
absence of IL-33.
RA is characterized by bone resorption and cartilage
destruction. IL-33 is involved in bone resorption [34],
and osteoblasts isolated from IL-33 transgenic mouse
can produce significant bone matrix in vitro [34]. Add-
itionally, the number of osteoclasts is decreased in these
animals. ST2-deficient mice, with decreased bone dens-
ity together with increased osteoclast number, showed
an anti-osteoclastogenic effect of IL-33. Moreover, ad-
ministration of IL-33 in human TNF-α transgenic mice,
with spontaneous development of arthritis, inhibited
bone destruction and reduced the number of osteoclasts
[35]. Taken together, these studies show the inhibitory
effect of IL-33 on osteoclasts and led us to evaluate oste-
oclastogenesis for the first time. Osteoclast formation
was induced by culturing isolated bone marrow cells
with RANKL and M-CSF for 5 days, followed by TRAP
staining and revealed comparable osteoclastogenesis in
IL-33-/- and WT mice.
However, the resorption activity of a synthetic bone
matrix by osteoclasts was higher in IL-33-/- than WT mice.
The differences were not statistically significant, probably
because of the low number of animals used in this study.
To our knowledge, IL-33 is not produced by osteoclasts.
However, it might be produced by osteoclast precursors
present at the initial periods of culture. As well, the osteo-
clast phenotype may be differentially regulated in vivo in
IL-33-/- mice and thus, the cells may respond to RANK-L
and M-CSF in vitro stimulation. In addition, the effect of
IL-33 on bone resorption may not be sufficient to change
the clinical evolution of CIA. IL-33 may not have a direct
role for osteoclasts but may exert its anti-osteoclastogenic
activity via other cells such as osteoblasts [36].
Fig. 7 Interleukin (IL)-33 expression and promoter activation in the skin during imiquimod (IMQ)-induced skin inflammation. Immunofluorescence
staining for IL-33 in skin samples 11 days after daily IMQ or Vaseline application. IMQ-treated IL-33-/- mice showed no expression of IL-33 (a),
whereas IMQ-treated wild-type (WT) mice showed IL-33 expression (red) in keratinocyte nuclei (b) as did WT mice without IMQ treatment (c). On
the bottom panel, the activity of the endogenous IL-33 promoter, by X-Gal staining, showed IMQ-treated IL-33-/- mice with expression in basal
layers of the epidermis (d) and no detection in WT mice (e) (×200)
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Conclusions
Even though IL-33 is expressed within the synovium of
arthritic mice, CIA develops independently of IL-33, and
in psoriasis, as well, its absence does not affect the T cell
shift toward Th1, Th17, or Treg subpopulations.
Altogether, these data suggest that this cytokine is not
crucial for chronic inflammation development. Studies
of RA patients are needed to determine whether treat-
ment targeting the IL-33/ST2 axis would be effective.
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